IBS Clinical Trial
— IBS-DOfficial title:
A Double-blind, Placebo-controlled Study to Assess the Effect of Probiotic on Symptom Relief and Indices of Micro-inflammation and Cholinergic Status in IBS Patients With Diarrhea.
Verified date | May 2018 |
Source | Tel-Aviv Sourasky Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
We present the study design of a clinical trial designed to assess the clinical effects of the multispecies probiotic combination "BIO-25" in IBS-D patients. To this aim the primary endpoints of the study will be improvement in abdominal pain and stool consistency. The study will also be designed and powered to investigate the effect of the probiotic BIO-25 on the putative inflammation-associated parameters related to microinflammation in IBS, using postulated improvements in Hs-CRP, and calprotectin as markers of that effect. Additional aims of the study will examine the possible effect of probiotic BIO-25 on the cholinergic status.
Status | Completed |
Enrollment | 107 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: A diagnosis of IBS-D according to the Rome III criteria, agreement to participate and the ability to sign an informed consent. Moreover, the definition of inclusion criteria is based on the FDA Draft Guidance for Clinical Evaluation of Products (add ref here). Over the two week run-in period: - Pain Intensity: weekly average of worst abdominal pain in past 24 hours score of = 3.0 on a 0 (no pain at all) to 10 (worst possible pain) point scale - Stool Consistency: =30% of days/week with at least one stool =6 using the Bristol Stool Score (BSS, Fig. 1) (ref). Exclusion Criteria: 1) Hyperthyroidism, 2) celiac disease 3) pregnancy, 4) other gastrointestinal diagnoses that might interfere with the study (e.g. active peptic disease, inflammatory bowel disease), 5) a history of malignancy that might, to the best judgment of the doctor, interfere with the study, 6) any infectious or inflammatory disease within the last month, 7) active medically treated asthma, 8) baseline levels of HsCRP > 10mg/liter, 9) steroid treatment for any indication, 10) fecal incontinence, and 11) treatment with probiotics or antibiotics of any kind within the last 4 weeks, 11) Diabetes. |
Country | Name | City | State |
---|---|---|---|
Israel | Tel-Aviv Sourasky Medical Center | Tel-Aviv | Central Israel |
Lead Sponsor | Collaborator |
---|---|
Tel-Aviv Sourasky Medical Center |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Symptom relief (abdominal pain and stool consistency) | Abdominal pain intensity, stool consistency, will be assessed by visual analogue scales (VAS) with scales from 0 (no symptom at all) to 10 (the worst possible symptom. The definition of treatment responders is based on the FDA Draft Guidance for Clinical Evaluation of Products for Treatment of Irritable Bowel Syndrome. A Pain Intensity Responder is a patient who experiences a 30% or greater decrease in the weekly average of worst abdominal pain in past 24 hours in the past 24 hours compared to baseline. A Stool Consistency Responder is a patient who has a greater than 50% decrease in the number of days with at least one stool = type 6 using the Bristol Stool Scale (BSS). A patient will be classified as an overall responder if they achieve the above improvement in pain intensity and stool consistency for at least 50 percent of the time. |
8 weeks | |
Secondary | Improvement in other specific IBS symptoms, i.e., gas and bloating, feeling of urgency | Specific IBS symptoms, i.e., gas and bloating, feeling of urgency, will be assessed by visual analogue scales (VAS) with scales from 0 (no symptom at all) to 10 (the worst possible symptom). | 8 weeks | |
Secondary | Reduce hs-CRP levels | Blood will be drawn from IBS-D patients after a 12-hour fast and will be analyzed for hs-CRP. | 8 weeks | |
Secondary | Improve the cholinergic status | Plasma cholinesterase catalytic activity measurements will involve adaptation of a spectrophotometric method to a microtiter plate assay | 8 weeks | |
Secondary | Reduce calprotectin levels | At the beginning and at the end of the treatment period, fecal samples will be obtained for the measurement of calprotectin levels. The quantitative concentration of calprotectin will be determined by enzyme linked immunosorbent assay (ELISA). |
8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04677881 -
Health Effects of Different Types of Bread
|
N/A | |
Completed |
NCT02293343 -
24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance
|
N/A | |
Completed |
NCT01717404 -
Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)
|
Phase 1 | |
Withdrawn |
NCT02313207 -
Confocal Laser Endomicroscopy in IBS Patients
|
N/A | |
Completed |
NCT02937506 -
Patient Satisfaction With Propofol for Out Patient Colonoscopy
|
Phase 4 | |
Terminated |
NCT05579444 -
Systems Biology of Gastrointestinal and Related Diseases
|
||
Completed |
NCT02419963 -
Analyzing IBS to Identify Biomarkers and Microbiome Signatures
|
N/A | |
Recruiting |
NCT06389851 -
Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD
|
N/A | |
Recruiting |
NCT05815602 -
Ebastine Versus Mebeverine in IBS Patients
|
Phase 3 | |
Completed |
NCT03482765 -
A Study of Probiotics in IBS Subjects
|
N/A | |
Completed |
NCT03986476 -
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT06275906 -
Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters.
|
N/A | |
Not yet recruiting |
NCT05737277 -
Gabapral in Pediatric IBS
|
N/A | |
Active, not recruiting |
NCT05718505 -
Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
|
N/A | |
Recruiting |
NCT06072287 -
The Living With a Long-Term Condition Study
|
||
Completed |
NCT04953728 -
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
|
N/A | |
Completed |
NCT02681666 -
Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02981888 -
Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
|
||
Recruiting |
NCT01779765 -
The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
|
Phase 4 | |
Completed |
NCT02009618 -
The Effects of Rifaximin Therapy in Irritable Bowel Syndrome
|
N/A |